Bone Mineral Density Loss in Relapsing-remitting Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Matched Case-control Study
International Journal of Preventive Medicine · 2026-03 · 17
DOI: 10.4103/ijpvm.ijpvm_29_25 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift International Journal of Preventive Medicine, 2026-03. Verfasst von Elham Sadat Azimi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Prior studies have linked bone marrow density (BMD) with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). However, the risk of BMD loss and associated factors in relapsing remitting MS (RRMS) and NMOSD patients remains insufficiently evaluated. The objective of this study was to assess the risk of osteopenia and osteoporosis and identify associated factors in RRMS and NMOSD.
Methods
This matched case-control study was conducted in Isfahan, Iran, between November 2022 and November 2023. Patients diagnosed with RRMS and NMOSD, along with healthy controls (HCs), underwent densitometry of the femoral neck and lumbar spine regions. Osteopenia and osteoporosis were defined according to the WHO criteria, and associated risk factors were identified through logistic and linear regression analyses.
Results
The 30 RRMS and 30 NMOSD patients, as well as 35 age- and sex-matched healthy controls (HCs), were included. The odds of osteopenia or osteoporosis did not significantly differ between RRMS patients and HCs (odds ratio (OR) =1.7, P = 0.34). In contrast, NMOSD patients had a higher probability of developing these conditions than HCs (OR = 3.3, P = 0.02). BMD loss in RRMS was associated significantly with alkaline phosphatase (ALP) levels (OR = 1.1, P = 0.013), while in NMOSD, significant relationships were found with age (OR = 1.3, P = 0.013), EDSS (OR = 3.4, P = 0.02), physical activity (OR = 0.2, P = 0.02), ALP (OR = 1.2, P = 0.02), 25-hydroxy Vitamin D (vitamin D3) (OR = 0.9, P = 0.034), and phosphorus levels (OR = 0, P = 0.004).
Conclusions
Although no association was found between RRMS and BMD loss, NMOSD increased the risk of BMD loss threefold compared with HCs. Clinicians are advised to routinely evaluate these patients and their risk factors for BMD loss and implement preventive measures accordingly.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
- School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
- Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Zitieren
APA
Azimi, E. S., Shaygannejad, A., Vaheb, S., Panah, M. Y., Mohammadi, M., Mokhtari Jazi, M. H., Ashtari, F., Shaygannejad, V., & Mirmosayyeb, O. (2026). Bone Mineral Density Loss in Relapsing-remitting Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Matched Case-control Study. International Journal of Preventive Medicine, 17. https://doi.org/10.4103/ijpvm.ijpvm_29_25
Vancouver
Azimi ES, Shaygannejad A, Vaheb S, Panah MY, Mohammadi M, Mokhtari Jazi MH, et al. Bone Mineral Density Loss in Relapsing-remitting Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Matched Case-control Study. International Journal of Preventive Medicine. 2026;17. doi:10.4103/ijpvm.ijpvm_29_25
BibTeX
@article{Azimi2026,
author = {Azimi, Elham Sadat and Shaygannejad, Aysa and Vaheb, Saeed and Panah, Mohammad Yazdan and Mohammadi, Mohammad and Mokhtari Jazi, Mohammad Hossein and Ashtari, Fereshteh and Shaygannejad, Vahid and Mirmosayyeb, Omid},
title = {Bone Mineral Density Loss in Relapsing-remitting Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Matched Case-control Study},
journal = {International Journal of Preventive Medicine},
year = {2026},
volume = {17},
doi = {10.4103/ijpvm.ijpvm_29_25}
}
EUVIMED